Related Experiment Video
Updated: Aug 29, 2026

A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Cutaneous angiosarcoma in a patient with xeroderma pigmentosum
Ilaria Marcon1, Paola Collini, Michela Casanova
1Pediatric Oncology Unit, Istituto Nazionale Tumori, Milan, Italy.
Abstract:
Xeroderma pigmentosum (XP) is a DNA repair defect syndrome associated with an increased risk to developing skin neoplasms on sun-exposed cutaneous surfaces. This report describes the case of a 15-year-old boy with XP who developed cutaneous angiosarcoma. The patient was cured with surgery alone, despite incomplete resection, and he is alive without evidence of disease 40 months after diagnosis. It is the fourth reported case--and the third in pediatric age--of the association of XP with this soft part sarcoma.
Insights
Xeroderma pigmentosum (XP), a DNA repair defect, increases skin cancer risk. This report details a pediatric case of cutaneous angiosarcoma in a 15-year-old XP patient, successfully treated with surgery.
Area of Science:
- Oncology
- Genetics
- Dermatology
Background:
- Xeroderma pigmentosum (XP) is a rare genetic disorder characterized by deficient DNA repair mechanisms.
- Individuals with XP have a significantly elevated risk of developing skin cancers, particularly on sun-exposed areas.
- Soft tissue sarcomas are rare malignancies, and their association with XP is infrequently reported.
Observation:
- This report presents a case of a 15-year-old male diagnosed with Xeroderma pigmentosum.
- The patient developed a rare form of soft tissue sarcoma, specifically cutaneous angiosarcoma.
- This represents the fourth documented instance of angiosarcoma in conjunction with XP and the third in a pediatric patient.
Findings:
- The patient underwent surgical resection for the cutaneous angiosarcoma.
- Despite incomplete tumor resection, the patient achieved a complete cure.
- The patient remains disease-free for 40 months post-diagnosis, indicating a favorable outcome.
Implications:
- This case highlights the potential for rare sarcoma development in XP patients.
- It suggests that aggressive surgical management can be effective even with incomplete resection in select XP cases.
- Further research into the oncogenic pathways in XP may reveal novel therapeutic targets for associated malignancies.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Pigmentation
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...